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Summary
Objective.— To analyse long-term adherence persistence of evidence-based medical therapy
in ‘real-world’ patients with coronary disease.
Methods.— Cardiologists recruited the ﬁrst three consecutive patients seen in either hospital
clinics or private practice in 2006 who had been hospitalized for an acute coronary syndrome
(ACS) in 2005 in France. Demographic characteristics, medical history, current treatments and
medications at hospital discharge were recorded. The primary outcome was the persistence of
the combination therapy comprising a beta-blocker, an antiplatelet, a statin and an angiotensin-
converting enzyme (ACE) inhibitor (BASI).
Results.— A total of 1700 patients were included in this French observational study. The mean
time from hospital discharge to consultation was 14± 4 months. At hospital discharge, BASI
had been prescribed in 46.2% of patients, 80.2% of whom were still taking the combination at
the consultation. Non-persistence was associated with severe noncardiovascular disease, atrial
ﬁbrillation and lack of signiﬁcant coronary artery stenosis. When analysed separately, beta-
blockers, antiplatelets, statins and ACE inhibitors had been prescribed at hospital discharge in
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82.4, 98.9, 89.2 and 58%, respectively. Persistence over the 14-months period was greater than
86% for each of the drug classes. After hospital discharge, BASI was initiated in 8.5% of patients.
Fourteen months after hospitalization for an ACS, 45.6% of patients were taking BASI.
Conclusions.— Long-term persistence of BASI remained high after hospital discharge for an ACS,
whereas the combination was started in a minority of those not discharged on this treatment.
Fourteen months after an ACS, only half of the patients were receiving BASI, mainly due to fail-
ure to prescribe an ACE inhibitor at discharge. Our results highlight the importance of hospital
prescription of BASI to obtain long-term persistence in ACS.
© 2008 Published by Elsevier Masson SAS.
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Résumé
But de l’étude.— Analyser la persistance sur le long terme des traitements fondés sur les
preuves chez les patients ayant présenté un syndrome coronaire aigu.
Méthodes.— Il s’agit d’une étude observationnelle conduite en France en 2006 par des cardio-
logues exerc¸ant en secteur libéral ou hospitalier. Chaque investigateur devait inclure les trois
premiers patients rec¸us en consultation et ayant été hospitalisés en 2005 pour un syndrome
coronaire aigu. Les caractéristiques cliniques, les traitements à la sortie de l’hôpital et en
cours le jour de la consultation d’inclusion étaient colligés. Le critère principal d’évaluation
était la persistance de la combinaison thérapeutique : bêtabloquant, antiagrégant plaquettaire,
statine, inhibiteur de l’enzyme de conversion (BASI).
Résultats.— 1700 patients ont été inclus. La durée moyenne entre la sortie de l’hôpital et
l’inclusion était de 14± 4 mois. À la sortie de l’hôpital, le traitement BASI était prescrit chez
46,2 % des patients et 80,2 % d’entre eux recevaient encore le traitement BASI lors de l’inclusion.
La non persistance du traitement BASI était corrélée avec la présence d’une pathologie sévère
non cardiovasculaire, d’une ﬁbrillation auriculaire et l’absence de sténose signiﬁcative des
artères coronaires. Analysés séparément, les bêtabloquants, les antiagrégants plaquettaires,
les statines et les inhibiteurs de l’enzyme de conversion étaient respectivement prescrits à la
sortie de l’hôpital chez 82,4, 98,9, 89,2 et 58 % des patients. Après la sortie de l’hôpital, le
traitement BASI était initié chez 8,5 % des patients.
Conclusion.— La persistance du traitement BASI est importante lorsqu’il est prescrit à la sortie
de l’hôpital, alors qu’il n’est initié que chez une minorité de patients qui ne le rec¸oit pas à
leur sortie d’hôpital. Quatorze mois après une hospitalisation pour un syndrome coronaire aigu,
seulement la moitié des patients rec¸oit un traitement par BASI, principalement en raison d’un
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ackground
large volume of evidence demonstrates that beta-blockers
B), antiplatelets agent (A), statins (S), and angiotensin-
onverting enzyme (ACE) inhibitors (I) have a beneﬁcial
mpact on cardiovascular outcome in patients with a history
f coronary disease [1—4]. In secondary prevention, the
ower the concentration of low-density lipoprotein (LDL)
holesterol, the better is the outcome [5]. A similar rela-
ionship has been suggested between blood pressure and
ardiovascular prognosis in patients with diabetes, and to a
esser extent in those with coronary disease [6—10]. Thus,
isk factor control (C) is a cornerstone of the management
f patients at high cardiovascular risk. In light of these data,
uropean recommendations raised the concept of BASIC for
atients with coronary disease [10]. This concept is intended
o promote widespread use of combination treatment com-
rising a beta-blocker, an antiplatelet, a statin and an ACE
nhibitor (BASI) in this population and to enhance risk factor
ontrol. In the ‘‘real world’’, however, many obstacles can
eopardize the implementation of evidence-based recom-
endations. Patients seen in everyday clinical practice
re more likely to have comorbidities or to experience
d
C
w
d
wbiteur de l’enzyme de conversion à leur sortie de l’hôpital.
sson SAS.
reatment side effects than those enrolled in randomized
rials. Subjects in clinical trials often have better adherence
o medications than do patients seen in everyday practice.
inally, in contrast to what happens in the ‘‘real world’’, the
lose follow-up of patients in randomized trials enhances
he safety, and thus, the beneﬁt of pharmacological treat-
ents, as shown with spironolactone in the treatment
f congestive heart failure [11,12]. Practitioners faced
ith these problems may be reluctant to continue with
vidence-based treatments initiated during hospitalization.
hus, it is of paramount importance to analyse, using ‘‘real-
orld’’ data, persistence of combination of evidence-based
edical therapy in patients with coronary disease.
ethods
he nationwide cross-sectional PREVENIR-4 study was con-
ucted in a representative group of cardiologists in France.
linicians based in public and private hospital departments
ere randomly selected from a comprehensive national
atabase comprising all French cardiologists. The sample
as regionally stratiﬁed to ensure the representativeness
py 303
Table 1 Characteristics of the study population
(n = 1700).
Age (years)a 63.9± 11.8
Body mass index (kg/m2)a 26.6± 4.0
Systolic blood pressure (mmHg)a 131.8± 15.8
Diastolic blood pressure (mmHg)a 77.0± 8.9
Time since acute coronary
syndrome (months)a
14.1± 4.0
Obesity (body mass
index > 30 kg/m2)
281 (16.5)
Men (%) 1332 (78.4)
Cardiovascular risk factors (%)
Treated hypertension 938 (55.2)
Treated dyslipidaemia 1379 (81.1)
Treated diabetes 307 (18.1)
Current smoking 176 (10.4)
Cardiovascular history (%)
Left-ventricular ejection
fraction < 40%
159 (9.4)
Disabling stroke 27 (1.6)
Atrial ﬁbrillation 152 (9.0)
Severe noncardiovascular diseaseb
(%)
305 (18.0)
Discharge diagnosis (%)
Acute coronary syndrome
STEMI 621 (36.5)
NSTEMI 369 (21.7)
Unstable angina 710 (41.8)
Angiographic data available(%) 1652 (97.2)
No signiﬁcant coronary artery
stenosis
50 (2.9)
One-vessel disease 661 (38.9)
Two-vessel disease 545 (32.1)
Three-vessel disease 396 (23.3)
Percutaneous transluminal
coronary angioplasty (%)
1321 (77.7)
Drug-eluting stent (%) 674 (49.0)
Bare-metal stent (%) 708 (53.6)
Coronary artery bypass graft (%) 167 (9.8)
STEMI, ST-segment elevation myocardial infarction, NSTEMI,
non-ST-segment elevation myocardial infarction.
a Median± standard deviation.
b Depression, Alzheimer’s disease or dementia, severe renal fail-
l
t
(
l
f
ﬁPersistence of combination of evidence-based medical thera
of the study with regard to French medical practice. A total
of 5599 cardiologists were contacted by mail, of which 792
gave their consent to participate and signed the study proto-
col. The reasons for declining to participate were collected
for all cardiologists contacted.
Among the 621 cardiologists who enrolled at least one
assessable patient into the study, 254 (41.9%) were in private
practice, 130 (21.5%) were in hospital departments, and 222
(36.6%) had both private and hospital practices. Their mean
age was 47.9± 8.3 years and 507 (82.7%) were men. Data
were unavailable for 15 (1%) cardiologists.
Investigators were instructed to recruit the ﬁrst three
patients seen at their practice in 2006 who had been hospi-
talized for an acute coronary event (ST-segment elevation
myocardial infarction, non-ST-segment elevation myocardial
infarction or unstable angina) in 2005. Data were collected
on patients’ demographic characteristics, lifestyle habits,
education level, working status, cardiovascular history, con-
comitant diseases, and medications at hospital discharge
and at inclusion into the study. Height, weight, last LDL
cholesterol and fasting glycaemia measurements available
in the medical record were noted. Blood pressure was mea-
sured in a standardized manner.
Clinical outcomes
The primary outcome was the persistence BASI, deﬁned as
the proportion of patients prescribed BASI at discharge who
were still taking the combination at the time of the con-
sultation. Secondary outcomes were the persistence of the
individual treatments, and control of risk factors, deﬁned as
blood pressure less than 140/90mmHg, LDL cholesterol less
than 1 g/L, and fasting glycaemia less than 1.26 g/L.
Statistical analysis
Data are summarized as frequencies and percentages for
categorical data. Independent determinants of adherence
to BASI were assessed using a multivariate logistic regression
model. Variables found to be signiﬁcantly correlated with
the persistance of BASI in univariate analysis were intro-
duced into the model as variables. Statistical analysis was
performed using SAS statistical software (SAS/STAT user’s
guide, release 6.12. Cary, North Carolina, USA: SAS Institute
Inc, 1997). A signiﬁcance level less than 0.05 was considered
statistically signiﬁcant.
Results
The study population comprised 1700 patients recruited by
621 cardiologists in all French regions in 2006 (Table 1).
The mean time from hospital discharge to inclusion in the
study was 14± 4 months. At hospital discharge, BASI was
prescribed in 46.2% of patients, and was still being used in
80.2% at 14 months (Table 2). At the inclusion visit, 37.1% of
the patients prescribed BASI at discharge were still receiving
this treatment. After hospital discharge, BASI was initiated
in 8.5% of patients. Fourteen months after hospitalization
for an acute coronary syndrome (ACS), 45.6% of the subjects
were receiving BASI.
A
p
l
rure, respiratory failure, cancer, cirrhosis.
When considered separately, beta-blockers, antiplate-
ets, statins and ACE inhibitors were prescribed at hospi-
al discharge in 82.4, 98.9, 89.2 and 58.0%, respectively
Table 2). Persistence of each of these drug classes was at
east 86%.
Among patients prescribed BASI at discharge (Table 3),
ailure to continue with BASI was associated with atrial
brillation, severe noncardiovascular disease (depression,
lzheimer’s disease or dementia, severe renal failure, res-
iratory failure, cancer, cirrhosis), and lack of signiﬁcant
uminal narrowing of coronary arteries on angiography.
The relation between persistence of BASI and control of
isk factors is shown in Table 4. Overall, poor risk factor
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Table 3 Independent predictors of non persistence of
BASI.
Odds
ratio
95% conﬁdence
interval
P value
History of atrial
ﬁbrillation
(yes vs no)
2.98 1.65—5.41 < 0.001
At least one severe
noncardiovascular
disease
(yes vs no)
1.72 1.09—2.73 0.02
Signiﬁcant coronary 0.21 0.07—0.6 < 0.01
c
t
o
g
1
N
o
c
w
D
W
p
a
t
m
a
i
t
t
b
t
a
i
a
e
c
s
b
i
s
o
s
w
t
w
c
i
l
a
Fstenosis ( > 50%)
(yes vs no)
ontrol was observed: 51.9% (487 of 938) of treated hyper-
ensive patients reached blood pressure goals and 46.8% (645
f 1379) of patients with treated dyslipidaemia reached tar-
et LDL-cholesterol goals. Fasting glycaemia was less than
.26 g/L in 38.1% (117 of 307) of treated diabetic patients.
o signiﬁcant difference was observed in the persistence
f BASI according to hypertension control and fasting gly-
aemia less than 1.26 g/L. However, the persistence of BASI
as positively associated with control of LDL-cholesterol.
iscussion
e report three salient ﬁndings from this study. First, among
atients in whom BASI was prescribed at hospital discharge,
dherence remained high, at 80.2%. Second, less that half of
he patients hospitalized for an ACS were receiving BASI 14
onths after discharge. Third, the persistence of BASI was
ssociated with control of cardiovascular risk factors.
The results of our study emphasize the impact of
n-hospital prescription on long-term treatment: the persis-
ence of BASI remained high. After hospital discharge, this
reatment was initiated in only 8.5% of patients. Data from
oth randomized trials and observational studies underline
he importance of evidence-based treatments on survival
fter an ACS [13—17]. Our results highlight the need to
mprove hospital treatment, beyond revascularization ther-
py, in patients admitted for an ACS. Moreover, periodic
valuation of secondary prevention treatments in outpatient
linics would be useful, perhaps in a collegial way. It is reas-
uring to note, however, that two of three variables found to
e negatively correlated with the persistence of BASI were
n line with good medical practice. First, we showed that
evere noncardiovascular diseases have a negative impact
n the persistence of BASI. In these patients, it seems rea-
onable to alleviate the burden of preventive treatments
hen a severe noncardiovascular disease jeopardizes short-
erm vital prognosis. It is also reassuring to compare our data
ith those derived from a community-based data analysis
onducted in patients admitted for myocardial infarction
n the Netherlands between 1991 and 2000 [18]. In this
arge observational study, the persistence at one year of
ny combination evidence-based medical therapy was 68%.
urthermore, in 2000, 48% of the patients received an oral
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Table 4 Persistence of BASI according to risk factor control.
Treated hypertensivesa
(n = 938)
Blood pressure (mmHg)
Treated dyslipidaemiab
(n = 1379)
LDL cholesterol (g/L)
Treated diabetesc
(n = 307)
Fasting glycaemia (g/L)
< 140/90 ≥ 140/90 NA ≤ 1 > 1 NA < 1.26 ≥ 1.26
n = 487 n = 451 n = 263 n = 645 n = 471 n = 72 n = 117 n = 118
Adherence (%) 184 (37.8) 171 (37.9) 106 (40.3) 270 (41.9) 154 (32.7) 26 (36.1) 45 (38.5) 38 (32.2)
NA, not available.
a Non-signiﬁcant difference in the persistence according to hypertension control; P = 0.94 (2 test).
b The persistence was positively associated with LDL-cholesterol control; P = 0.004 (2 test).
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Rc Non-signiﬁcant difference in the persistence of BASI according t
antithrombotic plus a beta-blocker and/or an ACE inhibitor
plus a statin at hospital discharge. In our more contemporary
study, conducted in 2006, we showed that 46% of patients
received discharge treatment with an antiplatelet, a beta-
blocker, an ACE inhibitor, and a statin. These data therefore
suggest a slow but signiﬁcant improvement in the manage-
ment of ACS over the past decade (there only appears to be
an improvement in adherence, not discharge prescription).
Second, we showed that atrial ﬁbrillation was negatively
associated with the persistence of BASI. This result under-
lines the lack of clear evidence comparing antiplatelet
therapy with antivitamin K in this population. Finally, a lack
of signiﬁcant coronary stenosis negatively impacts on the
persistence of BASI. This failure of persistence of evidence-
based treatment is questionable; indeed, in many cases,
the culprit lesion is not associated with signiﬁcant luminal
narrowing [19].
The second main ﬁnding from our nationwide study is that
14 months after an ACS, in less than half of the patients
were receiving BASI. Whereas beta-blockers, antiplatelets
and statins were still being used in more than 80% of
patients, ACE inhibitors were used in only half. Thus,
ACE inhibitors appear to be the rate-limiting factor in
the prescription of BASI. Differences in the levels of evi-
dence could account in part for this result. Indeed, only
the European trial on reduction of cardiac events with
perindopril in patients with stable coronary artery disease
(EUROPA) trial [4] clearly supported the positive impact of
ACE inhibitors on cardiovascular outcomes in patients with
coronary lesions independently of left ventricular function.
However, in the Prevention of events with angiotensin-
converting enzyme inhibition (PEACE) trial [20], trandolapril
failed to demonstrate any signiﬁcant effect, and around half
of the patients included in the Heart outcomes prevention
evaluation (HOPE) study [21] were free of coronary disease.
In line with these data, the current study suggests that
practitioners remain to be convinced of the beneﬁts of ACE
inhibitors for patients with coronary disease independent of
ventricular ejection fraction.
The third main result from our study was that control
of blood pressure and fasting glycaemia was not negatively
inﬂuenced by adherence to BASI, whereas control of LDL
cholesterol was positively correlated with it. This is a key
issue — risk factor control appeared to be as disappointing as
that in previous observational studies [22—24]. Conversely,
the beneﬁcial effects of BASI are thought to be partlyting glycaemia; P = 0.92 (2 test).
ndependent of risk factor control. Importantly, with LDL-
holesterol control, the present results suggest that in the
‘real world’’ both logics can coexist and may even act syn-
rgistically.
onclusions
ur data highlight the importance of prescribing BASI at hos-
ital discharge for an ACS. Long-term persistence of BASI
emained high, at 80.2%, whereas this combination was ini-
iated after discharge in only 8.5% of cases. Fourteen months
fter the index ACS, less than half of patients were still
eceiving BASI, mainly due to failure to prescribe an ACE
nhibitor at discharge. Finally, the persistence of BASI was
ositively correlated with risk factor control.
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